| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.088 | 0.01 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.094 | 0.01 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.02 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.02 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.02 |
| mRNA | Epothilone B | FIMM | pan-cancer | AAC | 0.4 | 0.02 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | -0.074 | 0.02 |